Targeted protein degradation of the Y220C-p53 mutant as a potential anti-cancer strategy

Miller, Hollie (2024) Targeted protein degradation of the Y220C-p53 mutant as a potential anti-cancer strategy. MRes thesis, University of Glasgow.

Full text available as:
[thumbnail of 2023MillerMRes.pdf] PDF
Download (2MB)


Targeted protein degradation and Proteolysis Targeting Chimeras (PROTACs) in particular, have become an exciting new field in the drug discovery world, with the potential to target previously seen as ‘undruggable’ proteins. With many PROTACs now reaching the clinic, it is clear that these new modalities have the potential to become therapeutically successful and to overcome problems previously observed with traditional small molecule drugs. One of the most frequently mutated proteins in human cancers, p53 has been a particularly challenging drug target for many years. The work presented in this thesis provides a strategy in which to target and degrade the common Y220C p53 mutant by utilising the PROTAC degradation mechanism.

In particular, PROTAC 2 was found to degrade the Y220C p53 mutant at a low micromolar concentration and hence provides insight into the potential these PROTACs hold for the future as potent degraders of target proteins.

Item Type: Thesis (MRes)
Qualification Level: Doctoral
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
Colleges/Schools: College of Science and Engineering > School of Chemistry
Supervisor's Name: France, Dr. David and Huang, Professor Danny
Date of Award: 2024
Depositing User: Theses Team
Unique ID: glathesis:2024-84041
Copyright: Copyright of this thesis is held by the author.
Date Deposited: 19 Jan 2024 15:57
Last Modified: 19 Jan 2024 15:59
Thesis DOI: 10.5525/gla.thesis.84041

Actions (login required)

View Item View Item


Downloads per month over past year